Animal models to study cognitive impairment of chronic kidney disease.

Autor: Imenez Silva PH; Institute of Physiology, University of Zurich, Zurich, Switzerland.; Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands., Pepin M; Institut National de la Santé et de la Recherche Médicale U-1018 Centre de Recherche en Épidémiologie et Santé des Population, Équipe 5, Paris-Saclay University, Versailles Saint-Quentin-en-Yvelines University, Villejuif, France.; Department of Geriatrics, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris Université Paris-Saclay, Paris, France., Figurek A; Institute of Anatomy, University of Zurich, Zurich, Switzerland., Gutiérrez-Jiménez E; Center for Functionally Integrative Neuroscience, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Bobot M; Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistance Publique-Hopitaux de Marseille, and INSERM 1263, Institut National de la Recherche Agronomique 1260, C2VN, Aix-Marseille Universitaire, Marseille, France., Iervolino A; Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli,' Naples, Italy., Mattace-Raso F; Division of Geriatrics, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Hoorn EJ; Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands., Bailey MA; Edinburgh Kidney, Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, United Kingdom., Hénaut L; UR UPJV 7517, Jules Verne University of Picardie, Amiens, France., Nielsen R; Department of Biomedicine, Aarhus University, Aarhus, Denmark., Frische S; Department of Biomedicine, Aarhus University, Aarhus, Denmark., Trepiccione F; Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli,' Naples, Italy., Hafez G; Department of Pharmacology, Faculty of Pharmacy, Altinbas University, Istanbul, Turkey., Altunkaynak HO; Department of Pharmacology, Gulhane Faculty of Pharmacy, University of Health Sciences, Istanbul, Turkey., Endlich N; Department of Anatomy and Cell Biology, University Medicine Greifswald, Greifswald, Germany., Unwin R; Department of Renal Medicine, Royal Free Hospital, University College London, London, United Kingdom., Capasso G; Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli,' Naples, Italy.; Biogem Research Institute, Ariano Irpino, Italy., Pesic V; Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia., Massy Z; Centre for Research in Epidemiology and Population Health, INSERM UMRS 1018, Clinical Epidemiology Team, University Paris-Saclay, University Versailles-Saint Quentin, Villejuif, France.; Department of Nephrology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris Université Paris-Saclay, Paris, France., Wagner CA; Institute of Physiology, University of Zurich, Zurich, Switzerland.
Jazyk: angličtina
Zdroj: American journal of physiology. Renal physiology [Am J Physiol Renal Physiol] 2024 Jun 01; Vol. 326 (6), pp. F894-F916. Date of Electronic Publication: 2024 Apr 18.
DOI: 10.1152/ajprenal.00338.2023
Abstrakt: Mild cognitive impairment (MCI) is common in people with chronic kidney disease (CKD), and its prevalence increases with progressive loss of kidney function. MCI is characterized by a decline in cognitive performance greater than expected for an individual age and education level but with minimal impairment of instrumental activities of daily living. Deterioration can affect one or several cognitive domains (attention, memory, executive functions, language, and perceptual motor or social cognition). Given the increasing prevalence of kidney disease, more and more people with CKD will also develop MCI causing an enormous disease burden for these individuals, their relatives, and society. However, the underlying pathomechanisms are poorly understood, and current therapies mostly aim at supporting patients in their daily lives. This illustrates the urgent need to elucidate the pathogenesis and potential therapeutic targets and test novel therapies in appropriate preclinical models. Here, we will outline the necessary criteria for experimental modeling of cognitive disorders in CKD. We discuss the use of mice, rats, and zebrafish as model systems and present valuable techniques through which kidney function and cognitive impairment can be assessed in this setting. Our objective is to enable researchers to overcome hurdles and accelerate preclinical research aimed at improving the therapy of people with CKD and MCI.
Databáze: MEDLINE